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Abstract
The impact of mapping the human proteome: Globally, the health care organizations are under resource and
cost constrains due to the increasing number of patients that are due to a fast increase of the 65+ age group
requiring extensive medical hospitalization and treatments. Hospitals worldwide strive to seek the best cure for
patients, suffering from various diseases. A consequence of these global changes, of healthy populations in relation
to patients forms the basis for the build of large and centralized biobank facilities, with strategies where the search
for an understanding of diseases at a molecular level is at heart. The efforts made lies within large governmental
resource allocations where patient centers are collecting samples from clinical study participants in order to try to
discover universal expression patterns and molecular signatures of disease and disease stages. Most developments
in this area are aimed towards the discovery, and understanding diagnosis implementations. By providing the right
treatment alternatives for patients care, at the right time point i.e., at a given disease stage development becomes a
major goal where pharmaceutical industry, academia and the health care sector joins forces in large clinical
epidemiological, population-, and disease based studies. This becomes a clear strategic link to the enhancement
and prospects for personalized medicines and target directed diagnosis developments (Companion Diagnostics),
which require coordinated efforts across a wide range of disciplines. Currently, companion diagnostics is at the core
of the personalized medicine paradigm shift. It will identify patients who are most likely to benefit from a particular
therapeutic product, as well as identify patients likely to be at increased risk for serious adverse reactions as a result
of treatment with a particular therapeutic agent. It is predicted that more than half of all new drugs will require a
companion diagnostic, which opens up for an endeavor for Proteomics research implementations.
Biobanking and bio-repositories
Global healthcare changes forms the basis for the rapid
development of centralized large scale biobank facilities,
with strategies to improve on patient status at hospitals
where limited resources are at hand [1,2].
Finding the [atient group of responders to a given
medical treatment is hospitals today is a major challenge.
Especially as we are entering a period of targeted drug
treatments. The consequence is that large clinical epi-
demiological, population-, and disease based studies are
undertaken to get an overall higher efficacy as well as an
improved safety assessment where Companion Diagnos-
tics will play a major role [3-5].
Biobanks were found to be within the ten ideas chan-
ging the world right now [6]. Biobank repositories
requires biobank sustainability where adequate staffing,
including pathology support is integrated into the health
care organization of hospitals.
The molecular value of information that is the treasure
of a biobank is illustrated in Figure 1.
Blood fractions from patients comprising whole blood,
serum, plasma (EDTA, citrate, and heparin) are being
stored and processed by automated processing in -80C
storage units. High-density sample tube systems are
applied to maximize the sample output per patient util-
izing 384-rack systems [7]. Bar code assignments ensure
the uniqueness of each and every sample that is used
within the analysis process generating both MS-MS and
antibody read-outs. The workflow and processing of
Biobank samples to generate extensive protein sequence
information in health and disease is outlined in Figure 2.
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The current status of healthcare requests and demands
can be summarized by that currently more than 7,000
rare diseases affect human mankind and less than 200
have available pharmacotherapy [8].
Considering an estimated number of 20,300 proteins
within the Human Proteome, coded by the genome, will
increase and reach into several million proteins after
cellular processing, the key protein targets to be
considered is a real challenge. Thus, the C-HPP consor-
tia deliveries over the next coming years will be instru-
mental in these development programs.
These difficult healthcare issues will entail large num-
ber of biobank samples with ample statistical power.








Figure 1 Schematic illustration of the molecular targets and drivers that will form the basis for future drugs and diagnostics in







Figure 2 Biobank work flow where large scale Biobanks are utilized for high-throughput protein sequencing using mass
spectrometry platforms.
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and exploit these cohort sample assets in order to gener-
ate value in future science milestones that will transform
value to the patient.
Biobanks of human patient samples tissues and blood
fractions are increasingly recognized as major assets in
disease research [9,10]. These new sample archives are
built within both academic, commercial health care, the
drug development industry, as well as within the govern-
ment regulating agencies.
Biobank samples are increasingly used as a major re-
source for scientists to access unique patient samples for
medical research and patient treatments. Many studies
within clinical proteomics utilize stored samples contained
in biobanks to measure specific protein expressions. For
Biobank samples stored in either −20C or −80C (the
preferable temperature), there is still today a debate on
how to reach a consensus on how best to provide:
 Sampling procedures and protocols
 Management and storage conditions
 Specific sample and Data assignments to sample
tubes linked to the barcode identifier
 LIMS and IT/IS solutions allowing sample tracking
ability
All these efforts are performed in order to reach goals
where these efforts are turned into value for the patient.
Standardizations of quality control of samples being
processed for storage as well as retrieval of stored
samples are important goals in order to support the de-
velopment of both drug targets as well as diagnostic
tools such as biomarkers.
Currently the highest unmet need in modern healthcare
is the monitoring and prediction of response to treatment.
The optimization of drug treatment that easily can be
adjusted for by scheduling the dosing, discontinuing, the
drug treatment, and thereby optimize and improve on the
safety and/or efficacy of a targeted drug treatment [11,12].
Consequently, the status today is that the lack of available
high quality sample collections with a wide range of
disease cohorts currently is a rate-limiting step for drug
development, medical research and novel diagnostics.
Ultimately, the C-HPP global project initiative will aid
by increasing the awareness within the proteomics
community regarding the basic concepts of clinical
samples. Understanding and standardizing the qualita-
tive requirements of clinical samples in order to generate
protein analysis data that can be globally shared and
used for future developments within our society will also
form the basis for improving on the data quality of
proteomic studies. Currently, the attritions of drugs are
51% due to efficacy, and 20% for safety, in relation to as
low as 1% due to pharmacokinetic properties [11]. This
means that the drug development processes that include
drug design and synthesis followed by physicochemical
property optimization of drugs, is currently the strong
part of pharma pipeline strategy. Consequently, it is im-
perative to understand the role of drugs and what they
do in patients. Areas such as:
 The disease link
 The link ofMode of drug action to the patho-physiology
 Disease mechanisms that relates to molecular
pathways
 Genetics and selected Protein targets with high drug
affinities
That needs to be aligned with the:
 Patient Stratification selecting the right phenotype (s)
 Potential responders within the patient cohort
 Individual risk assessments
The targeted Personalized Medicine developments ul-
timately will need to align with the increasing safety
demands that are key for preventive medicine and early
treatment. Another challenge for new drug developments,
where the C-HPP deliveries can play a role are disease
phases and complex patho-physiology that needs to be
understood for any given treatment.
Conclusions
Translating basic science to discover new and better
treatments is an enormous challenge where the un-
derstanding of protein function(s), both as targets as well
as biomarkers will bring great value in the near future to
come. This includes the missing proteins (currently
about 30% of the human proteome) that have not yet
been identified on a protein level but predicted from
DNA, or identified as transcripts. Another area where
the C-HPP will have an important role to play is within
the area of the future healthcare with drug and diagnos-
tic developments for novel treatments of complex
diseases. The future direction envisions that large studies
will be accompanied by, biological-, and molecular-
information and corresponding material from large
numbers of patients and healthy persons, where the pro-
tein data from large biobank archives will play a
mandatory role. Accordingly, there is a call for further
develop value and treasure that biobanking holds with a
global approval on the quality, standardization and the
organization of modern units being developed for future
use. There are also demands and expectations from na-
tional agencies on quality for a successful usage of
biobank materials, particularly in the area of novel drug
developed with accompanying diagnostics introduced
into the hospitals.
Marko-Varga Clinical and Translational Medicine 2013, 2:4 Page 3 of 4
http://www.clintransmed.com/content/2/1/4
Acknowledgement
This work was supported by grants from Mrs. Berta Kamprad Foundation,
Swedish Academy of Pharmaceutical Sciences, Swedish Research Council,
the Swedish Foundation for Strategic Research, Vinnova, Ingabritt & Arne
Lundbergs forskningsstiftelse and the Crafoord Foundation.
Received: 11 December 2012 Accepted: 12 December 2012
Published: 6 February 2013
References
1. Marko-Varga G, et al: Understanding drug uptake and binding within
targeted disease micro-environments in patients: a New tool for
translational medicine. Clin Translat Med 2012, 1:8.
2. LaBaer J: Improving international research with clinical specimens: 5
achievable objectives. J Proteome Res 2012, 11:5592.
3. Hamburg MA, Collins FS: The path to personalized medicine. N Engl J Med
2010, 363:301.
4. Marko-Varga GA, Végvári Á, Fehniger TE: Public service review. European
Union 2011, 21:250–252.
5. Hewitt RE: Biobanking: the foundation of personalized medicine. Curr
Opin Oncol 2011, 23:112.
6. Park A: Time; 2009.
7. Malm J, et al: Large scale biobanking of blood - the importance of high
density processing procedures. J Proteomics 2012, 76:116.
8. Bevilacqua G, et al: The role of the pathologist in tissue banking:
European consensus expert group report. Virchows Arch 2010, 456:449.
9. Paik YK, et al: The chromosome-centric human proteome project for
cataloging proteins encoded in the genome. Nat Biotechnol 2012, 30:221.
10. Miller G: Is pharma running Out of brainy ideas? Science 2010, 329:502.
11. Wagner JA, Williams SA, Webster CJ: Biomarkers and surrogate End points
for Fit-for-purpose development and regulatory evaluation of New
drugs. Clin Pharmacol Ther 2007, 81:104.
12. Végvári Á, Welinder C, Lindberg H, Fehniger TE, Marko-Varga G: Biobank
resources for future patient care: developments, principles and
concepts. J Clin Bioinformatics 2011, 1:24.
doi:10.1186/2001-1326-2-4
Cite this article as: Marko-Varga: BioBanking as the central tool for
translational medicine CTM issue 2013. Clinical and Translational Medicine
2013 2:4.
Submit your manuscript to a 
journal and beneﬁ t from:
7 Convenient online submission
7 Rigorous peer review
7 Immediate publication on acceptance
7 Open access: articles freely available online
7 High visibility within the ﬁ eld
7 Retaining the copyright to your article
    Submit your next manuscript at 7 springeropen.com
Marko-Varga Clinical and Translational Medicine 2013, 2:4 Page 4 of 4
http://www.clintransmed.com/content/2/1/4
